Literature DB >> 17472612

Posaconazole susceptibility testing against Candida species: comparison of broth microdilution and E-test methods.

G Sóczó1, G Kardos, P M McNicholas, E Falusi, L Gergely, L Majoros.   

Abstract

Posaconazole (POS) is a newer triazole with activity against yeasts and moulds. POS and fluconazole were tested in vitro against 32 Candida albicans, 30 C. glabrata, 21 C. tropicalis, 29 C. krusei, 28 C. parapsilosis, 50 C. inconspicua, 13 C. kefyr and 5 C. famata isolates using CLSI broth microdilution method (BMD). We compared E-test and a modified BMD using polyethylene-glycol (PEG) as solvent to the CLSI method. BMDs and E-test were performed according to CLSI and the manufacturer's instructions respectively. Geometric means of POS MICs using BMD were 0.71, 0.22 and 0.21 microg ml(-1) against C. glabrata, C. krusei and C. inconspicua, respectively, and remained below 0.1 microg ml(-1) against all other species tested. One of two C. albicans and two of three C. glabrata isolates resistant to fluconazole showed MICs above 8 microg ml(-1) to POS. The impact of using PEG instead of DMSO had only a minor effect (agreements above 95% with the exception of C. parapsilosis). E-tests read after 24 h showed good agreement with the BMD. POS exhibited excellent in vitro activity against Hungarian Candida strains. E-test showed good correlation with the CLSI method, but to facilitate the comparability of results we believe that DMSO should be used as solvent in the BMD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17472612     DOI: 10.1111/j.1439-0507.2007.01356.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  1 in total

1.  Antifungal susceptibility testing of Candida species isolated from the immunocompromised patients admitted to ten university hospitals in Iran: comparison of colonizing and infecting isolates.

Authors:  Parisa Badiee; Hamid Badali; Teun Boekhout; Kambiz Diba; Abdolkarim Ghadimi Moghadam; Ali Hossaini Nasab; Hadis Jafarian; Rasoul Mohammadi; Hossein Mirhendi; Mohammad Javad Najafzadeh; Ahmad Shamsizadeh; Jafar Soltani
Journal:  BMC Infect Dis       Date:  2017-11-21       Impact factor: 3.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.